Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) ...

With an estimated 1.5 lakh cases of oral cancer diagnosed annually in India and a high mortality rate due to late detection, ...

Visualizing cells after editing specific genes can help scientists learn new details about the function of those genes. But ...

Stocks Sink as Investors Worry About China’s A.I. Advances A jolt of panic hit technology stocks on Monday, with investors rattled by fears that A.I. advances by Chinese upstarts could threaten ...

Perth Zoo's last female elephant has left for her forever home in South Australia. Locals report seeing sparking and smoke near a power transmitter close to Arthur River, where a bushfire ripped ...

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

Virgin Voyages has kicked off 2025 with a bang, with a 60 percent increase in revenue and a 40 percent jump in new bookings. MSC Cruises is bringing its fourth World-class ship to a world class ...